Interesting Article from MDLinx

MDLinx  Psychiatry

5 minutes to stay current

Your Article Summary

Efficacy of atomoxetine in adults with attention deficit hyperactivity disorder: An integrated analysis of the complete database of multicenter placebo-controlled trials
Journal of Psychopharmacology, 07/31/14
Asherson P, et al. – In this study, authors found that ATX had a clinically significant effect in adults with ADHD, with reductions in core symptoms and clinically meaningful responder rates.
  • They performed an integrated analysis of all Eli Lilly–sponsored, randomized, double–blind, placebo–controlled studies of ATX in adults with ADHD completed as of May 2012.
  • Individual patient data were pooled from six short–term (10–16 week) studies (1961 patients) and three longer–term (six–month) studies (1413 patients).

  • In the short–term analysis, ATX patients achieved a significantly greater mean reduction in ADHD symptoms than placebo patients (–12.2 vs –8.1; Conners' Adult ADHD Rating Scale–Investigator–Rated: Screening Version (CAARS–Inv: SV); p<0 data-blogger-escaped-.001="" data-blogger-escaped-li="">
  • In the longer–term analysis, respective improvements after six months were –13.2 vs –9.7 (p<0 data-blogger-escaped-.001="" data-blogger-escaped-li="">
  • Response rates at study endpoints for ATX vs placebo, based on CAARS–Inv: SV improvement ≥30% and Clinical Global Impressions of ADHD–Severity (CGI–ADHD–S) ≤3 were 34.8% vs 22.3% in the short–term and 43.4% vs 28.0% after six months, and CAARS–Inv: SV improvements ≥40% were 41.3% vs 25.3% in the short–term and 44.0% vs 31.4% after six months (all p<0 data-blogger-escaped-.001="" data-blogger-escaped-li="">

Receive more summaries like this by joining MDLinx. We provide free daily digests of top journal articles in your field. >> Click here to choose your specialties.

Other articles in Psychiatry

>> Click here to see the complete list

No comments:

HOME (*Revenire-Pagina la Zi)